Organogenesis Inc. is Recipient of a 'Best of Biotech' Award.Business/Technology Editors & Health/Medical Writers CANTON, Mass.--(BW HealthWire)--Dec. 7, 2000 Organogenesis organogenesis /or·ga·no·gen·e·sis/ (or?gah-no-jen´e-sis) the origin and development of organs.organogenet´ic or·gan·o·gen·e·sis n. The formation and development of the organs of living things. Inc. (AMEX AMEX See: American Stock Exchange :ORG) today announced its receipt of a Best of Biotech award for the Company's achievement of the product Apligraf(R) for the treatment of diabetic foot diabetic foot A foot with a constellation of pathologic changes affecting the lower extremity in diabetics, often leading to amputation and/or death due to complications; the common initial lesion leading to amputation is a nonhealing skin ulcer, induced by ulcers. Award selection was based on the voting of biotechnology chief executive officers - business leaders in the industry. Apligraf is the first, and only, mass-produced product containing living human cells to prove efficacy and gain FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. marketing approval. In June 2000, Apligraf was approved for use in diabetic foot ulcers; the product was previously approved for use in venous leg ulcers. The development of Apligraf has required state-of-the-art expertise in many disciplines, including mammalian cell culture, cellular differentiation Cellular differentiation is a concept from developmental biology describing the process by which cells acquire a "type". The morphology of a cell may change dramatically during differentiation, but the genetic material remains the same, with few exceptions. and immunology. Leading the Company's research program is Nancy Parenteau, Ph.D., Chief Scientific Officer and Senior Vice President, Research and Development, a world leader in tissue engineering. In addition to her many scientific publications, book chapters and presentations, Dr. Parenteau serves by invitation on key organizations involved in shaping the future of the field. She recently served as a panel member for the prestigious World Technology Evaluation (WTEC WTEC World Technology Evaluation Center ) Study on Tissue Engineering commissioned by several governmental agencies including the National Science Foundation, US Food and Drug Administration, National Institutes of Health, the Department of Commerce and the Department of Defense. Dr. Parenteau is also a member of the federal National Research Council's Chemical Sciences Roundtable and is on the Board of the Pittsburgh Tissue Engineering Initiative. The Company's clinical and regulatory programs are under the leadership of Michael Sabolinski, M.D., Senior Vice President, Medical and Regulatory Affairs. In addition to achieving the only FDA approvals in the field for a mass-produced product containing living human cells, Dr. Sabolinski presents frequently at national and international conferences on wound-healing and has a number of clinical publications in the field. Dr. Sabolinski accepted the Award on behalf of Organogenesis at the 13th annual biotechnology CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. meeting in Laguna Niguel, California Laguna Niguel is a city located in southern Orange County, California. The name "Laguna Niguel" is derived from the Spanish word "Laguna" which means lagoon and the word "Nigueli" which was the name of a Juaneno Indian village once located on Aliso Creek. . "We are proud of our state-of-the-art tissue engineering expertise," said Philip Laughlin, President and Chief Executive Officer. "We are pleased to now be gaining recognition not only in the scientific and medical communities, but also in the business community. We are applying this expertise to bringing other exciting products to market." The Company's product development focus includes living tissue replacements, cell-based organ assist devices and other tissue-engineered products. Apligraf is a cellular, bi-layered skin substitute; Novartis Pharma AG has global Apligraf marketing rights. The Organogenesis research pipeline includes the VITRIX(TM) living dermal dermal /der·mal/ (der´mal) pertaining to the dermis or to the skin. der·mal or der·mic adj. Of or relating to the skin or dermis. replacement product, a coronary vascular graft and a liver assist device. Apligraf(R) is a registered trademark of Novartis. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion